Free Trial
OTCMKTS:SCCYF

Scythian Biosciences (SCCYF) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
6,589 shs
Average Volume
76,011 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Scythian Biosciences

Scythian Biosciences Corp. engages in the research and development of cannabinoid-based combination drug therapies for the treatment of concussions and traumatic brain injury. It also develops drug candidates for the treatment of gastro-intestinal inflammatory issues. The company is headquartered in Toronto, Canada.

SCCYF Stock News Headlines

See More Headlines
Receive SCCYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scythian Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:SCCYF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Brady Cobb
    CEO & Director
  • Mr. Peter D. Liabotis CPA (Age 48)
    CA, Chief Financial Officer
  • Mr. Maghsoud Dariani (Age 65)
    Chief Scientific Officer
  • Prof. Michael Barnes
    Chief Medical Officer
  • Mr. Gabriel Meneses
    VP of Latin America & Caribbean

This page (OTCMKTS:SCCYF) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners